Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Roche receives exclusive worldwide rights to ZW209, a DLL3-targeting trispecific T-cell engager, materially outsourcing development and commercialization.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Roche receives exclusive worldwide rights to ZW209, a DLL3-targeting trispecific T-cell engager, materially outsourcing development and commercialization
- $55 million upfront payment, plus $40 million upon Phase Ib initiation
- Up to $718 million in research, development, commercial, and sales milestones
- Tiered high-single-digit to mid-teen royalties on net sales, subject to customary reductions
- Zymeworks funds Phase Ia activities at Roche’s expense, while Roche assumes later development, manufacturing, and commercialization costs
Item 7.01 · Regulation FD Disclosure
- Press release announces information regarding Zymeworks’ Collaboration and License Agreement
- Agreement update may affect strategic partnerships, licensing economics, and future revenue potential
Item EX-99.1 · Exhibit EX-99.1
- Exclusive global Roche license for ZW209, transferring subsequent development and commercialization responsibility to Roche
- $55 million upfront plus $40 million upon Phase 1b initiation, improving near-term funding visibility
- Up to $718 million in additional milestones plus tiered high-single-digit to mid-teen royalties on global net sales
- Zymeworks retains Phase 1a collaboration, while Roche funds the trial and assumes later global development costs
- Closing remains subject to HSR waiting-period expiration and customary regulatory conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.